Ignite Creation Date:
2024-05-05 @ 11:26 PM
Last Modification Date:
2024-10-26 @ 10:34 AM
Study NCT ID:
NCT01339988
Status:
UNKNOWN
Last Update Posted:
2011-04-21
First Post:
2011-04-20
Brief Title:
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation TBI and Cyclophosphamide for Hematological Malignancies Hematocrit HCT
Sponsor:
Tel-Aviv Sourasky Medical Center
Organization:
Tel-Aviv Sourasky Medical Center
Study Overview
Official Title:
Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation TBI and Cyclophosphamide to Examine Results Success and Side Effects of Treatment With Chemotherapy Only as a Preparative Therapy for Patients With Cord Blood Transplants
Status:
UNKNOWN
Status Verified Date:
2011-04
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation TBI which are most marked in children radiated at a young age Growth failure decline in cognitive function and endocrine abnormalities have all been described Good outcomes can be achieved with alkylating agents only as a preparative regimen This plan will use a combination of busulfan and cyclophosphamide BuCy with or without antithymocyte globulin ATG to reduce the late toxicities of therapy that includes TBI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None